[18F]FDG PET/CT in a Case of Mycosis Fungoides Showing an Unusual Adverse Reaction to Mogamulizumab: Correlation Between Imaging and Histological Findings.
暂无分享,去创建一个
O. Schillaci | L. Filippi | I. Proietti | V. Petrozza | O. Bagni | C. Potenza | F. Fiorentino | S. Aversa | M. Cantonetti
[1] S. Rowe,et al. Molecular imaging in oncology: Current impact and future directions , 2021, CA: a cancer journal for clinicians.
[2] C. Nervi,et al. Molecular imaging in immuno-oncology: current status and translational perspectives , 2020, Expert review of molecular diagnostics.
[3] P. Zinzani,et al. Critical concepts and management recommendations for cutaneous T‐cell lymphoma: A consensus‐based position paper from the Italian Group of Cutaneous Lymphoma , 2020, Hematological oncology.
[4] Xuelei Ma,et al. Safety and efficacy profile of mogamulizumab (Poteligeo) in the treatment of cancers: an update evidence from 14 studies , 2020, BMC cancer.
[5] U. Wehkamp,et al. Should we be imaging lymph nodes at initial diagnosis of early-stage mycosis fungoides? Results from the PROCLIPI international Study. , 2020, The British journal of dermatology.
[6] A. Rook,et al. Mogamulizumab in the treatment of advanced mycosis fungoides and Sézary syndrome: safety and efficacy , 2020, Expert review of anticancer therapy.
[7] K. Tada,et al. Increase of DC-LAMP+ mature dendritic cell subsets in dermatopathic lymphadenitis of mycosis fungoides , 2014, European Journal of Dermatology.
[8] R. Warnke,et al. Staging accuracy in mycosis fungoides and sezary syndrome using integrated positron emission tomography and computed tomography. , 2006, Archives of dermatology.